

September 18, 2018

**BSE Limited** 

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531 Scrip code: STAR

Dear Sirs,

Sub: Completion of USFDA inspection at Bangalore facility

We wish to inform you that the formulations facility in Bangalore recently underwent pre- approval product inspection by the USFDA. The inspection ended on August 25, 2018 and the company has been issued a Form 483 with 3 observations. The Company believes that the observations are not material in nature and we have already responded to the USFDA.

The Company has recently (post completion of the inspection) received a product approval for Potassium Chloride Extended Release Tablets from this facility.

You are requested to take the same on record.

For Strides Pharma Science Limited

Sd/-Manjula Ramamurthy Company Secretary The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex

Bandra (E) Mumbai - 400 051